Shaping the future of pharma
Email: info@amarintech.com.ar
New tools for more precise drug delivery systems Kimbelery Pardo – Marketing and Business Development Analyst The pharmaceutical industry is undergoing a period of profound transformation driven by the convergence of materials science, biology, and technology. In this context, smart biomaterials and nanotechnology are emerging as key tools for the [...]
Dermocosmetic patches are not a recent invention. More than 3,000 years ago, Chinese and Egyptian cultures were already applying pharmaceutical preparations to the skin for therapeutic purposes. What is recent is the sophistication of the format: today, that same transdermal delivery logic is applied to cosmetic actives with technical precision [...]
Ensuring adhesion throughout the use of a medicinal patch is crucial for providing safe and reliable products. Discover how an adhesive overlay can be the solution to adhesion problems and the challenges its formulation presents. From compatibility with the active ingredient to the ideal size and the ability to avoid [...]
According to the World Health Organization, the abusive consumption of certain drugs and substances has increased in recent years, resulting in serious consequences for the population, including neurological damage, motor disabilities, addiction, overdoses, and even death. While traditional pharmaceutical forms such as tablets are frequently abused, transdermal patches, especially those [...]
Transdermal patches present specific attributes that determine their efficacy, safety, and quality, and that must be controlled in the laboratory through analytical techniques to ensure the performance and safety of the transdermal delivery system (TDS). Some correspond to tests common to other pharmaceutical forms. However, due to the particular characteristics [...]
The use of Quality by Design (QbD) concept to medicated plasters (patches) development gives us the certainty to obtain safety and reliable products for patients with verifiable efficacy, long before they enter their production stage. [...]
The clinical requirements for generic transdermal patch approval are substantially more demanding than those for conventional oral dosage forms. A generic tablet typically needs to demonstrate pharmacokinetic bioequivalence in a single crossover study. A generic patch requires bioequivalence under single and multiple dose schemes, statistical non-inferiority in adhesion performance, and [...]